FDA Extends Hemispherx’s NDA Review Date for Ampligen

Hemispherx Biopharma has received a letter from the Food and Drug Agency indicating that the originally scheduled Prescription Drug User Fee Act date on the Ampligen New Drug Application (NDA) would be extended by three months “in order to provide time for a full review of the submission.”
MSNBC